Mark Wilson Biography and Net Worth

Mark A. Wilson was appointed Senior Vice President and General Counsel in December 2017. In this role, Mr. Wilson oversees all legal matters pertaining to the company, including contracts, corporate governance, securities law, SEC reporting, litigation, and all intellectual property matters including patent, copyright, and trademark matters. Mr. Wilson has over 20 years in the legal field, with a particular emphasis on intellectual property. Prior to his appointment as Nektar’s General Counsel in July 2016, Mr. Wilson led Nektar’s intellectual property department with oversight for the company's extensive patent portfolio, including the preparation and prosecution of patent applications.

Prior to joining Nektar in 2002, Mr. Wilson was an associate at Reed & Associates, a patent law firm in Menlo Park, California, where he successfully represented both early-stage and Fortune 500 companies.

Mr. Wilson received his J.D. from Seton Hall University, School of Law, and his B.S. in pharmacy from Rutgers University, College of Pharmacy. He is registered to practice before the U.S. Patent and Trademark Office and is a member of the California Bar.

What is Mark Andrew Wilson's net worth?

The estimated net worth of Mark Andrew Wilson is at least $868,870.92 as of August 16th, 2022. Mr. Wilson owns 281,188 shares of Nektar Therapeutics stock worth more than $868,871 as of February 5th. This net worth approximation does not reflect any other assets that Mr. Wilson may own. Learn More about Mark Andrew Wilson's net worth.

What is Mark Andrew Wilson's salary?

As the SVP of Nektar Therapeutics, Mr. Wilson earned a total compensation package of $3,503,661.00 in 2021. Mr. Wilson earned a salary of $500,000.00, stock awards of $1,707,078.00, options awards of $998,320.00, non-equity compensation of $287,500.00, and other compensation of $10,763.00. Learn More on Mark Andrew Wilson's salary.

How do I contact Mark Andrew Wilson?

The corporate mailing address for Mr. Wilson and other Nektar Therapeutics executives is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. Nektar Therapeutics can also be reached via phone at (415) 482-5300 and via email at [email protected] Learn More on Mark Andrew Wilson's contact information.

Has Mark Andrew Wilson been buying or selling shares of Nektar Therapeutics?

Mark Andrew Wilson has not been actively trading shares of Nektar Therapeutics over the course of the past ninety days. Most recently, Mark Andrew Wilson sold 3,189 shares of the business's stock in a transaction on Tuesday, August 16th. The shares were sold at an average price of $4.76, for a transaction totalling $15,179.64. Following the completion of the sale, the senior vice president now directly owns 281,188 shares of the company's stock, valued at $1,338,454.88. Learn More on Mark Andrew Wilson's trading history.

Who are Nektar Therapeutics' active insiders?

Nektar Therapeutics' insider roster includes Robert Chess (Director), Myriam Curet (Director), Gil Labrucherie (CFO), John Northcott (SVP), Howard Robin (CEO), Jillian Thomsen (CAO), Mark Wilson (SVP), and Jonathan Zalevsky (Insider). Learn More on Nektar Therapeutics' active insiders.

Are insiders buying or selling shares of Nektar Therapeutics?

During the last year, insiders at the biopharmaceutical company sold shares 20 times. They sold a total of 314,077 shares worth more than $1,549,090.27. The most recent insider tranaction occured on November, 16th when insider Jonathan Zalevsky sold 13,460 shares worth more than $48,052.20. Insiders at Nektar Therapeutics own 3.4% of the company. Learn More about insider trades at Nektar Therapeutics.

Information on this page was last updated on 11/16/2022.

Mark Andrew Wilson Insider Trading History at Nektar Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/16/2022Sell3,189$4.76$15,179.64281,188View SEC Filing Icon  
5/16/2022Sell3,136$3.95$12,387.20117,939View SEC Filing Icon  
8/16/2021Sell1,910$13.83$26,415.30200,915View SEC Filing Icon  
5/17/2021Sell1,917$18.30$35,081.10207,107View SEC Filing Icon  
2/3/2021Sell5,344$19.45$103,940.80View SEC Filing Icon  
8/17/2020Sell1,529$19.67$30,075.43View SEC Filing Icon  
See Full Table

Mark Andrew Wilson Buying and Selling Activity at Nektar Therapeutics

This chart shows Mark Andrew Wilson's buying and selling at Nektar Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Nektar Therapeutics Company Overview

Nektar Therapeutics logo
Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.
Read More

Today's Range

Now: $3.09
Low: $2.89
High: $3.15

50 Day Range

MA: $2.55
Low: $2.03
High: $3.10

2 Week Range

Now: $3.09
Low: $1.99
High: $11.59


1,509,001 shs

Average Volume

1,310,673 shs

Market Capitalization

$580.77 million

P/E Ratio


Dividend Yield